Teacher Retirement System of Texas Sells 7,176 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Teacher Retirement System of Texas reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 49.6% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 7,280 shares of the company's stock after selling 7,176 shares during the quarter. Teacher Retirement System of Texas' holdings in Medpace were worth $2,419,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Pallas Capital Advisors LLC boosted its stake in Medpace by 179.7% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock valued at $1,086,000 after acquiring an additional 2,101 shares during the last quarter. Barclays PLC raised its holdings in shares of Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company's stock worth $6,603,000 after purchasing an additional 8,275 shares during the period. Sanctuary Advisors LLC lifted its stake in Medpace by 20.5% in the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock valued at $1,738,000 after purchasing an additional 844 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Medpace by 10.0% during the third quarter. Janus Henderson Group PLC now owns 44,118 shares of the company's stock valued at $14,722,000 after purchasing an additional 4,023 shares during the period. Finally, SYM FINANCIAL Corp purchased a new stake in Medpace in the fourth quarter worth $320,000. Institutional investors own 77.98% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MEDP shares. Leerink Partners assumed coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Robert W. Baird increased their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. Finally, Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $376.30.

Remove Ads

Medpace Stock Down 1.3 %

Shares of Medpace stock traded down $4.25 during trading on Friday, hitting $312.36. 343,137 shares of the stock traded hands, compared to its average volume of 298,736. The firm's fifty day moving average is $335.90 and its 200-day moving average is $339.18. The stock has a market cap of $9.52 billion, a price-to-earnings ratio of 24.73, a PEG ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.